Evidence map›Paper›PMID 42698906›Full record

ArticleSynthetic and systems biotechnology2027

Strategy for enhanced production of A40926B0 in

Xiaoru Wang, Hongmei Zhai, Dandan Gu, Yongchao Wang, Jiali Gao, Luxi Du, Liuxu Zhuo, Xiaobing Li, Yu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic and systems biotechnology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoru WangCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Hongmei ZhaiCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Dandan GuCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Yongchao WangCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Jiali GaoCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Luxi DuCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Liuxu ZhuoCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Xiaobing LiCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.
Yu WangCollege of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, 050035, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global emergence of vancomycin-resistant Gram-positive pathogens underscores the urgent need for efficient production of novel lipoglycopeptide antibiotics. Dalbavancin, a last-resort therapeutic agent, relies on its key biosynthetic precursor A40926B0, whose industrial manufacture is severely limited by the low yield of wild-type

Indexed as

A40926B0Branched-chain fatty acidCRISPR/AsCas12f1DalbavancinMetabolic engineeringNonomuraea gerenzanensisShikimate pathway

Identifiers

PMID42698906
PMCPMC13543061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.